Pacific Biosciences of California Stock | PACB | US69404D1081 | A1C3EQ | July 2025

Date	Pacific Biosciences of California Price
7/4/2025	0 undefined
7/3/2025	1.60 undefined
7/2/2025	1.47 undefined
7/1/2025	1.29 undefined
6/30/2025	1.25 undefined
6/27/2025	1.28 undefined
6/27/2025	1.27 undefined
6/26/2025	1.28 undefined
6/25/2025	1.20 undefined
6/24/2025	1.20 undefined
6/23/2025	1.19 undefined
6/20/2025	1.25 undefined
6/20/2025	1.29 undefined
6/18/2025	1.31 undefined
6/18/2025	1.31 undefined
6/17/2025	1.31 undefined
6/16/2025	1.37 undefined
6/13/2025	1.19 undefined
6/13/2025	1.18 undefined
6/12/2025	1.18 undefined
6/11/2025	1.18 undefined
6/10/2025	1.18 undefined
6/9/2025	1.14 undefined
6/6/2025	1.12 undefined
6/6/2025	1.14 undefined
6/5/2025	0.99 undefined

Date	Pacific Biosciences of California Revenue	Pacific Biosciences of California EBIT	Pacific Biosciences of California Net Income
2030e	470.93 M undefined	0 undefined	-19.6 M undefined
2029e	302.67 M undefined	-114.19 M undefined	-95.19 M undefined
2028e	266.3 M undefined	-131.44 M undefined	-92.95 M undefined
2027e	232.37 M undefined	-113.36 M undefined	-113.39 M undefined
2026e	188.62 M undefined	-152.01 M undefined	-145.59 M undefined
2025e	159.15 M undefined	-295.11 M undefined	-405.62 M undefined
2024	154.01 M undefined	-268.02 M undefined	-309.85 M undefined
2023	200.52 M undefined	-321.99 M undefined	-306.74 M undefined
2022	128.3 M undefined	-303.5 M undefined	-314.2 M undefined
2021	130.5 M undefined	-179.3 M undefined	-181.2 M undefined
2020	78.9 M undefined	-104.4 M undefined	29.4 M undefined
2019	90.9 M undefined	-100.5 M undefined	-84.1 M undefined
2018	78.6 M undefined	-101 M undefined	-102.6 M undefined
2017	93.5 M undefined	-89.8 M undefined	-92.2 M undefined
2016	90.7 M undefined	-71.2 M undefined	-74.4 M undefined
2015	92.8 M undefined	-52.1 M undefined	-31.7 M undefined
2014	60.6 M undefined	-62.9 M undefined	-66.2 M undefined
2013	28.2 M undefined	-77.5 M undefined	-79.3 M undefined
2012	26 M undefined	-94.3 M undefined	-94.5 M undefined
2011	33.9 M undefined	-109.8 M undefined	-109.4 M undefined
2010	1.7 M undefined	-140.2 M undefined	-140.2 M undefined
2009	100,000 undefined	-88.1 M undefined	-87.7 M undefined
2008	900,000 undefined	-44.8 M undefined	-43.8 M undefined
2007	2.2 M undefined	-23.4 M undefined	-21.5 M undefined
2006	2 M undefined	-11.9 M undefined	-11.7 M undefined
2005	1.4 M undefined	-10.9 M undefined	-10.9 M undefined

	Revenue	EBIT	Net Income
2005	1.4 M USD	-10.9 M USD	-10.9 M USD
2006	2 M USD	-11.9 M USD	-11.7 M USD
2007	2.2 M USD	-23.4 M USD	-21.5 M USD
2008	900,000 USD	-44.8 M USD	-43.8 M USD
2009	100,000 USD	-88.1 M USD	-87.7 M USD
2010	1.7 M USD	-140.2 M USD	-140.2 M USD
2011	33.9 M USD	-109.8 M USD	-109.4 M USD
2012	26 M USD	-94.3 M USD	-94.5 M USD
2013	28.2 M USD	-77.5 M USD	-79.3 M USD
2014	60.6 M USD	-62.9 M USD	-66.2 M USD
2015	92.8 M USD	-52.1 M USD	-31.7 M USD
2016	90.7 M USD	-71.2 M USD	-74.4 M USD
2017	93.5 M USD	-89.8 M USD	-92.2 M USD
2018	78.6 M USD	-101 M USD	-102.6 M USD
2019	90.9 M USD	-100.5 M USD	-84.1 M USD
2020	78.9 M USD	-104.4 M USD	29.4 M USD
2021	130.5 M USD	-179.3 M USD	-181.2 M USD
2022	128.3 M USD	-303.5 M USD	-314.2 M USD
2023	200.52 M USD	-321.99 M USD	-306.74 M USD
2024	154.01 M USD	-268.02 M USD	-309.85 M USD
2025e	159.15 M USD	-295.11 M USD	-405.62 M USD
2026e	188.62 M USD	-152.01 M USD	-145.59 M USD
2027e	232.37 M USD	-113.36 M USD	-113.39 M USD
2028e	266.3 M USD	-131.44 M USD	-92.95 M USD
2029e	302.67 M USD	-114.19 M USD	-95.19 M USD
2030e	470.93 M USD	0 USD	-19.6 M USD

2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024

0.11	0.09	0.28	0.18	0.1	0.11	0.1	0.08	0.07	0.06	0.1	0.05	0.32	1.04	0.77	0.63	0.39
0	0	0.3	4.6	2.8	2.7	3.4	5.2	11.4	13.4	8.6	15.3	16.8	24.2	18.8	36.62	27.52
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	6.9	15.5	9.6	10.1	11.3	11	15.6	23.1	17.9	13.3	14.2	24.6	50.4	56.68	58.76
0.9	1	2.2	2.1	2	1.1	1.7	12.1	10	2.2	2.8	3.4	5.7	7.9	10.6	17.34	19.47
0.11	0.09	0.29	0.2	0.11	0.13	0.12	0.11	0.11	0.1	0.13	0.08	0.36	1.1	0.85	0.74	0.5
6	7.1	12.3	18.4	14.3	9.2	6.6	8.5	14.6	37.9	34.1	62.9	54.9	79.1	81.3	69.03	46.6
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	411	410.2	456.98	389.57
0	0	0	0	0	0	0	0	0	0	0	0	0	410	410	462.26	317.76
0.2	0.2	0.3	0.3	0.4	0.5	0.2	12	14.3	4.5	4.5	4	3.5	5.8	13.5	15.7	10.84
0.01	0.01	0.01	0.02	0.01	0.01	0.01	0.02	0.03	0.04	0.04	0.07	0.06	0.91	0.92	1	0.76
0.11	0.1	0.31	0.22	0.13	0.14	0.12	0.13	0.14	0.14	0.17	0.15	0.41	2.01	1.77	1.75	1.26

201.1	269.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.2	0.2	0.2	0.2	0.2	0.27	0.29
0.01	0.01	0.61	0.63	0.65	0.68	0.74	0.79	0.87	0.97	1.1	1.12	1.37	2.01	2.1	2.54	2.65
-104.3	-192	-332.2	-441.6	-536	-615.3	-681.5	-713.2	-787.5	-879.7	-982.1	-1,066.2	-1,036.9	-1,218.1	-1,532.3	-1,839.08	-2,148.93
0	0	0	100	0	0	0	0	0	0	0	0	100	-1,100	-4,800	219	422
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
107.7	92	279.9	191.5	109.4	69.2	54.9	73.5	84.7	86.2	114.2	55	335.5	790.9	562.9	701.3	506.59
1.8	5.8	9.5	4.7	3	1.7	5.6	4.7	8.4	9.1	6.7	8.4	3.6	11	12	15.06	16.59
1.1	2.1	6.2	7.2	5.8	7.9	11.4	15.6	16.6	12.6	12.8	17.1	21.7	44	41.5	55.3	32.62
0.5	0.5	5.1	7.3	5.7	12.9	14.4	17.9	8.8	6.9	7.3	7.8	13.2	16.7	208	24.18	17.09
1.3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0.1	0.1	0.2	0	0	0	0	0	0	15.9	0	0	1.8	0.49	0
4.7	8.4	20.9	19.3	14.7	22.5	31.4	38.2	33.8	28.6	26.8	49.2	38.5	71.7	263.3	95.03	66.3
0	0	2.9	2.8	0	13.3	14.1	14.9	16.1	13.6	14.7	0	0	896.1	897.2	892.74	647.49
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0.7	0.7	2.1	4.7	5.6	31.1	24	4.4	3.3	15.7	14.7	43.9	40	248.2	43.7	56.94	40.06
0	0	0.01	0.01	0.01	0.04	0.04	0.02	0.02	0.03	0.03	0.04	0.04	1.14	0.94	0.95	0.69
0.01	0.01	0.03	0.03	0.02	0.07	0.07	0.06	0.05	0.06	0.06	0.09	0.08	1.22	1.2	1.04	0.75
0.11	0.1	0.31	0.22	0.13	0.14	0.12	0.13	0.14	0.14	0.17	0.15	0.41	2.01	1.77	1.75	1.26

2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023
-21	-43	-87	-140	-109	-94	-79	-66	-31	-74	-92	-102	-84	29	-181	-314	-306
1	2	4	5	5	6	5	4	3	3	8	7	7	6	7	10	19
0	0	0	0	0	0	0	0	0	0	0	0	0	0	-93	0	-11
1	0	4	2	-12	1	33	0	-31	-18	-6	5	-3	-2	21	-53	-58
3	4	7	19	24	19	19	21	25	40	42	46	17	3	208	173	170
0	0	0	0	0	0	1	1	1	1	1	1	1	0	6	14	15
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
-16	-38	-74	-122	-102	-76	-29	-51	-47	-67	-67	-66	-78	19	-111	-263	-259
-3	-5	-5	-5	-9	-1	0	-1	-3	-8	-10	-1	-2	-1	-5	-16	-8
-18	-10	18	-138	6	61	-33	19	8	-14	-1	-38	62	-219	-678	116	4
-15	-4	23	-132	15	63	-32	21	11	-6	8	-36	64	-218	-672	133	13
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	-1	0	0	0	19	0	0	0	-4	0	0	-16	895	-1	-1
0	120	68	318	7	2	23	41	36	65	73	107	8	233	326	11	204
0	0.12	0.07	0.32	0.01	0	0.04	0.04	0.04	0.07	0.07	0.11	0.03	0.25	1.17	0.01	0.11
0	0	0	0	0	0	0	0	0	0	0	0	18	34	-52	0	-93
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
-35	71	10	58	-88	-12	-20	10	-2	-16	0	2	10	52	379	-137	-145
-19.78	-44	-80.02	-127.26	-112.25	-78.52	-30.74	-53.08	-50.9	-76.14	-77.95	-68.28	-81.15	18.46	-117.11	-280.14	-268.02
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Pacific Biosciences of California Gross margin	Pacific Biosciences of California Profit margin	Pacific Biosciences of California EBIT margin	Pacific Biosciences of California Profit margin
2030e	24.85 %	0 %	-4.16 %
2029e	24.85 %	-37.73 %	-31.45 %
2028e	24.85 %	-49.36 %	-34.91 %
2027e	24.85 %	-48.78 %	-48.8 %
2026e	24.85 %	-80.59 %	-77.19 %
2025e	24.85 %	-185.43 %	-254.87 %
2024	24.85 %	-174.02 %	-201.18 %
2023	28.03 %	-160.58 %	-152.97 %
2022	41.08 %	-236.55 %	-244.89 %
2021	45.13 %	-137.39 %	-138.85 %
2020	41.32 %	-132.32 %	37.26 %
2019	38.06 %	-110.56 %	-92.52 %
2018	31.93 %	-128.5 %	-130.53 %
2017	37.11 %	-96.04 %	-98.61 %
2016	48.73 %	-78.5 %	-82.03 %
2015	57.65 %	-56.14 %	-34.16 %
2014	38.61 %	-103.8 %	-109.24 %
2013	22.7 %	-274.82 %	-281.21 %
2012	3.46 %	-362.69 %	-363.46 %
2011	38.35 %	-323.89 %	-322.71 %
2010	100 %	-8,247.06 %	-8,247.06 %
2009	100 %	-88,100 %	-87,699.99 %
2008	24.85 %	-4,977.78 %	-4,866.67 %
2007	24.85 %	-1,063.64 %	-977.27 %
2006	24.85 %	-595 %	-585 %
2005	24.85 %	-778.57 %	-778.57 %

	Gross margin	EBIT margin	Profit margin
2005	24.85 %	-778.57 %	-778.57 %
2006	24.85 %	-595 %	-585 %
2007	24.85 %	-1,063.64 %	-977.27 %
2008	24.85 %	-4,977.78 %	-4,866.67 %
2009	100 %	-88,100 %	-87,699.99 %
2010	100 %	-8,247.06 %	-8,247.06 %
2011	38.35 %	-323.89 %	-322.71 %
2012	3.46 %	-362.69 %	-363.46 %
2013	22.7 %	-274.82 %	-281.21 %
2014	38.61 %	-103.8 %	-109.24 %
2015	57.65 %	-56.14 %	-34.16 %
2016	48.73 %	-78.5 %	-82.03 %
2017	37.11 %	-96.04 %	-98.61 %
2018	31.93 %	-128.5 %	-130.53 %
2019	38.06 %	-110.56 %	-92.52 %
2020	41.32 %	-132.32 %	37.26 %
2021	45.13 %	-137.39 %	-138.85 %
2022	41.08 %	-236.55 %	-244.89 %
2023	28.03 %	-160.58 %	-152.97 %
2024	24.85 %	-174.02 %	-201.18 %
2025e	24.85 %	-185.43 %	-254.87 %
2026e	24.85 %	-80.59 %	-77.19 %
2027e	24.85 %	-48.78 %	-48.8 %
2028e	24.85 %	-49.36 %	-34.91 %
2029e	24.85 %	-37.73 %	-31.45 %
2030e	24.85 %	0 %	-4.16 %

Date	Pacific Biosciences of California Sales per Share	Pacific Biosciences of California EBIT per share	Pacific Biosciences of California Earnings per Share
2030e	1.72 undefined	0 undefined	-0.07 undefined
2029e	1.1 undefined	0 undefined	-0.35 undefined
2028e	0.97 undefined	0 undefined	-0.34 undefined
2027e	0.85 undefined	0 undefined	-0.41 undefined
2026e	0.69 undefined	0 undefined	-0.53 undefined
2025e	0.58 undefined	0 undefined	-1.48 undefined
2024	0.56 undefined	-0.98 undefined	-1.13 undefined
2023	0.79 undefined	-1.27 undefined	-1.21 undefined
2022	0.57 undefined	-1.35 undefined	-1.4 undefined
2021	0.64 undefined	-0.88 undefined	-0.89 undefined
2020	0.45 undefined	-0.6 undefined	0.17 undefined
2019	0.6 undefined	-0.66 undefined	-0.55 undefined
2018	0.58 undefined	-0.75 undefined	-0.76 undefined
2017	0.88 undefined	-0.85 undefined	-0.87 undefined
2016	1.02 undefined	-0.8 undefined	-0.84 undefined
2015	1.23 undefined	-0.69 undefined	-0.42 undefined
2014	0.86 undefined	-0.89 undefined	-0.94 undefined
2013	0.45 undefined	-1.23 undefined	-1.26 undefined
2012	0.47 undefined	-1.69 undefined	-1.7 undefined
2011	0.63 undefined	-2.04 undefined	-2.03 undefined
2010	0.03 undefined	-2.65 undefined	-2.65 undefined
2009	0 undefined	-1.76 undefined	-1.75 undefined
2008	0.02 undefined	-0.89 undefined	-0.87 undefined
2007	0.04 undefined	-0.47 undefined	-0.43 undefined
2006	0.04 undefined	-0.24 undefined	-0.23 undefined
2005	0.03 undefined	-0.22 undefined	-0.22 undefined

	Sales per Share	EBIT per share	Earnings per Share
2005	0.03 USD	-0.22 USD	-0.22 USD
2006	0.04 USD	-0.24 USD	-0.23 USD
2007	0.04 USD	-0.47 USD	-0.43 USD
2008	0.02 USD	-0.89 USD	-0.87 USD
2009	0 USD	-1.76 USD	-1.75 USD
2010	0.03 USD	-2.65 USD	-2.65 USD
2011	0.63 USD	-2.04 USD	-2.03 USD
2012	0.47 USD	-1.69 USD	-1.7 USD
2013	0.45 USD	-1.23 USD	-1.26 USD
2014	0.86 USD	-0.89 USD	-0.94 USD
2015	1.23 USD	-0.69 USD	-0.42 USD
2016	1.02 USD	-0.8 USD	-0.84 USD
2017	0.88 USD	-0.85 USD	-0.87 USD
2018	0.58 USD	-0.75 USD	-0.76 USD
2019	0.6 USD	-0.66 USD	-0.55 USD
2020	0.45 USD	-0.6 USD	0.17 USD
2021	0.64 USD	-0.88 USD	-0.89 USD
2022	0.57 USD	-1.35 USD	-1.4 USD
2023	0.79 USD	-1.27 USD	-1.21 USD
2024	0.56 USD	-0.98 USD	-1.13 USD
2025e	0.58 USD	0 USD	-1.48 USD
2026e	0.69 USD	0 USD	-0.53 USD
2027e	0.85 USD	0 USD	-0.41 USD
2028e	0.97 USD	0 USD	-0.34 USD
2029e	1.1 USD	0 USD	-0.35 USD
2030e	1.72 USD	0 USD	-0.07 USD

Segmente	2020	2019	2018
Product	65.42 M USD	77.74 M USD	66.36 M USD
Instrument	34.28 M USD	45.13 M USD	-
Consumable	31.14 M USD	32.62 M USD	-
Service and Other	13.47 M USD	13.15 M USD	12.27 M USD

	Product	Instrument	Consumable	Service and Other
2018	66.36 M USD	0 USD	0 USD	12.27 M USD
2019	77.74 M USD	45.13 M USD	32.62 M USD	13.15 M USD
2020	65.42 M USD	34.28 M USD	31.14 M USD	13.47 M USD

Date	Asia	Asia Pacific	Europe	North America	U [S]
2020	-	22.55 M USD	19.07 M USD	37.28 M USD	-
2019	-	26.61 M USD	19.6 M USD	44.68 M USD	-
2017	-	39.7 M USD	13.2 M USD	40.6 M USD	-
2016	19.9 M USD	-	20 M USD	50.8 M USD	-
2015	15 M USD	-	9 M USD	68.8 M USD	-
2014	15.7 M USD	-	10.1 M USD	-	34.8 M USD

	Asia	Asia Pacific	Europe	North America	U [S]
2014	15.7 M USD	0 USD	10.1 M USD	0 USD	34.8 M USD
2015	15 M USD	0 USD	9 M USD	68.8 M USD	0 USD
2016	19.9 M USD	0 USD	20 M USD	50.8 M USD	0 USD
2017	0 USD	39.7 M USD	13.2 M USD	40.6 M USD	0 USD
2019	0 USD	26.61 M USD	19.6 M USD	44.68 M USD	0 USD
2020	0 USD	22.55 M USD	19.07 M USD	37.28 M USD	0 USD

	Number of stocks
2005	50.1 M Aktien
2006	50.1 M Aktien
2007	50.1 M Aktien
2008	50.1 M Aktien
2009	50.1 M Aktien
2010	52.9 M Aktien
2011	53.9 M Aktien
2012	55.7 M Aktien
2013	62.8 M Aktien
2014	70.5 M Aktien
2015	75.6 M Aktien
2016	89.1 M Aktien
2017	105.7 M Aktien
2018	135.1 M Aktien
2019	152.5 M Aktien
2020	175 M Aktien
2021	204.1 M Aktien
2022	224.6 M Aktien
2023	253.63 M Aktien
2024	274.49 M Aktien
2025e	274.49 M Aktien
2026e	274.49 M Aktien
2027e	274.49 M Aktien
2028e	274.49 M Aktien
2029e	274.49 M Aktien
2030e	274.49 M Aktien

Date	EPS Estimate	EPS Actual	Quarterly report
3/31/2025	-0.19	-1.44 (-646.89 %)	2025 Q1
12/31/2024	-0.21	-0.49 (-133.89 %)	2024 Q4
9/30/2024	-0.23	-0.22 (3.93 %)	2024 Q3
6/30/2024	-0.24	-0.64 (-169.7 %)	2024 Q2
3/31/2024	-0.28	-0.29 (-3.24 %)	2024 Q1
12/31/2023	-0.29	-0.31 (-6.57 %)	2023 Q4
9/30/2023	-0.33	-0.26 (22.32 %)	2023 Q3
6/30/2023	-0.33	-0.28 (14.4 %)	2023 Q2
3/31/2023	-0.34	-0.36 (-6.13 %)	2023 Q1
12/31/2022	-0.37	-0.37 (-0.41 %)	2022 Q4
9/30/2022	-0.34	-0.34 (-0.5 %)	2022 Q3
6/30/2022	-0.33	-0.32 (2.97 %)	2022 Q2
3/31/2022	-0.31	-0.37 (-17.65 %)	2022 Q1
12/31/2021	-0.29	-0.31 (-7.27 %)	2021 Q4
9/30/2021	-0.22	-0.23 (-3.65 %)	2021 Q3
6/30/2021	-0.21	-0.21 (0.05 %)	2021 Q2
3/31/2021	-0.47	-0.45 (3.68 %)	2021 Q1
12/31/2020	0.32	0.37 (14.06 %)	2020 Q4
9/30/2020	-0.14	-0.14 (-2.41 %)	2020 Q3
6/30/2020	-0.18	-0.15 (18.3 %)	2020 Q2
3/31/2020	-0.16	-0.21 (-30.68 %)	2020 Q1
12/31/2019	-0.17	0 (100 %)	2019 Q4
9/30/2019	-0.15	-0.19 (-24.18 %)	2019 Q3
6/30/2019	-0.16	-0.16 (1.96 %)	2019 Q2
3/31/2019	-0.16	-0.2 (-29.03 %)	2019 Q1
12/31/2018	-0.14	-0.21 (-53.62 %)	2018 Q4
9/30/2018	-0.16	-0.19 (-21.87 %)	2018 Q3
6/30/2018	-0.17	-0.17 (0.82 %)	2018 Q2
3/31/2018	-0.2	-0.2 (-2.3 %)	2018 Q1
12/31/2017	-0.2	-0.18 (10.27 %)	2017 Q4
9/30/2017	-0.2	-0.19 (6.08 %)	2017 Q3
6/30/2017	-0.25	-0.26 (-4.75 %)	2017 Q2
3/31/2017	-0.24	-0.24 (-0.42 %)	2017 Q1
12/31/2016	-0.23	-0.21 (8.78 %)	2016 Q4
9/30/2016	-0.21	-0.19 (7.54 %)	2016 Q3
6/30/2016	-0.23	-0.21 (8.22 %)	2016 Q2
3/31/2016	-0.25	-0.23 (8.59 %)	2016 Q1
12/31/2015	-0.02	-0.02 (10.71 %)	2015 Q4
9/30/2015	-0.27	-0.26 (4.9 %)	2015 Q3
6/30/2015	-0.14	-0.16 (-14.04 %)	2015 Q2
3/31/2015	-0.28	-0.27 (1.96 %)	2015 Q1
12/31/2014	-0.27	-0.26 (1.96 %)	2014 Q4
9/30/2014	-0.16	-0.13 (20.34 %)	2014 Q3
6/30/2014	-0.28	-0.27 (3.74 %)	2014 Q2
3/31/2014	-0.28	-0.28 (0.18 %)	2014 Q1
12/31/2013	-0.28	-0.26 (6.98 %)	2013 Q4
9/30/2013	-0.31	-0.28 (8.5 %)	2013 Q3
6/30/2013	-0.36	-0.33 (8.61 %)	2013 Q2
3/31/2013	-0.38	-0.37 (3.52 %)	2013 Q1
12/31/2012	-0.38	-0.39 (-2.23 %)	2012 Q4
9/30/2012	-0.44	-0.41 (6.95 %)	2012 Q3
6/30/2012	-0.47	-0.4 (15.49 %)	2012 Q2
3/31/2012	-0.48	-0.5 (-5.04 %)	2012 Q1
12/31/2011	-0.51	-0.42 (17.65 %)	2011 Q4
9/30/2011	-0.6	-0.45 (24.86 %)	2011 Q3
6/30/2011	-0.63	-0.42 (33.72 %)	2011 Q2
3/31/2011	-0.69	-0.66 (4.04 %)	2011 Q1
12/31/2010	-0.92	-0.97 (-4.97 %)	2010 Q4

%	Name	Stocks	Change	Date
13.28963 %	ARK Investment Management LLC	36,478,441	434,079	3/31/2025
8.52202 %	Madrone Advisors, LLC	23,391,915	0	3/31/2025
7.96216 %	Edmond de Rothschild Asset Management (France) S.A.	21,855,180	508,700	3/31/2025
7.45081 %	SB Investment Advisers (UK) Limited	20,451,570	20,451,570	11/21/2024
7.45081 %	SoftBank Group Corp	20,451,570	0	3/31/2025
7.44587 %	BlackRock Institutional Trust Company, N.A.	20,438,007	-1,170,870	3/31/2025
5.90721 %	The Vanguard Group, Inc.	16,214,593	1,036,606	3/31/2025
3.48479 %	Nikko Asset Management Co., Ltd.	9,565,331	-613,170	3/31/2025
2.32418 %	State Street Global Advisors (US)	6,379,592	-47,383	3/31/2025
2.30146 %	Geode Capital Management, L.L.C.	6,317,242	54,317	3/31/2025
1.78099 %	T. Rowe Price Investment Management, Inc.	4,888,612	-8,232	3/31/2025
1.27510 %	Shimoda Holdings LLC	3,500,000	0	12/31/2023
1.20966 %	Jackson Square Partners, LLC	3,320,361	-1,788,905	3/31/2025
1.16327 %	Morgan Stanley & Co. LLC	3,193,034	223,367	3/31/2025
1.09294 %	Koss-Olinger Consulting, LLC	3,000,000	1,000,000	3/31/2025
0.81191 %	Northern Trust Investments, Inc.	2,228,607	-94,008	3/31/2025
0.80297 %	Millennium Management LLC	2,204,044	-14,861,287	3/31/2025
0.77290 %	Charles Schwab Investment Management, Inc.	2,121,524	-54,728	3/31/2025
0.76346 %	UBS Financial Services, Inc.	2,095,594	708,063	3/31/2025
0.39854 %	Senvest Management, LLC	1,093,954	0	3/31/2025
0.39246 %	Goldman Sachs Asset Management, L.P.	1,077,267	-1,400,546	3/31/2025
0.36431 %	Gibson (James R II)	1,000,000	1,000,000	3/31/2025
0.36431 %	Soros Fund Management, L.L.C.	1,000,000	-1,372,265	3/31/2025
0.35421 %	Bourne Lent Asset Management Inc.	972,255	28,500	3/31/2025
0.33477 %	HHLR Advisors, Ltd.	918,892	0	3/31/2025
0.32229 %	Nordea Funds Oy	884,642	367,457	3/31/2025
0.28139 %	BlackRock Financial Management, Inc.	772,375	-593	3/31/2025
0.28007 %	BlackRock Investment Management, LLC	768,769	3,921	3/31/2025
0.27502 %	Goldman Sachs & Company, Inc.	754,893	-1,487,292	3/31/2025
0.26368 %	Casdin Capital, LLC	723,767	-312,092	3/31/2025
0.26299 %	BlackRock Advisors (UK) Limited	721,863	-8,424	5/31/2025
0.25803 %	BlackRock Asset Management Ireland Limited	708,255	5,165	3/31/2025
0.25457 %	Mirae Asset Global Investments (USA) LLC	698,763	-14,324	3/31/2025
0.25386 %	Henry (Christian O)	696,812	-152,571	4/10/2025
0.24825 %	Vestmark Advisory Solutions, Inc	681,426	-215,632	3/31/2025
0.24691 %	Two Sigma Investments, LP	677,738	-603,739	3/31/2025
0.21583 %	BofA Global Research (US)	592,423	-1,265,773	3/31/2025
0.20648 %	Van (Oene Mark D)	566,763	17,887	4/10/2025
0.19955 %	Aperio Group, LLC	547,744	22,604	3/31/2025
0.18789 %	Mirador Capital Partners LP	515,734	289,148	3/31/2025
0.18219 %	TD Securities, Inc.	500,100	-349,900	3/31/2025
0.17787 %	XTX Markets LLC	488,237	488,237	3/31/2025
0.17314 %	Schweizerische Nationalbank	475,246	0	3/31/2025
0.17064 %	ArrowMark Colorado Holdings, LLC	468,382	0	3/31/2025
0.16393 %	BNY Mellon Asset Management	449,972	-300,848	3/31/2025
0.16307 %	Federated MDTA LLC	447,604	0	3/31/2025
0.16284 %	Dimensional Fund Advisors, L.P.	446,988	-49,828	3/31/2025
0.15985 %	Rhumbline Advisers Ltd. Partnership	438,775	20,153	3/31/2025
0.15151 %	Invesco Capital Management LLC	415,869	264,864	3/31/2025
0.14890 %	Universal-Investment-Gesellschaft mbH	408,700	408,700	3/31/2025
0.14573 %	Claresco Finance S.A.	400,000	0	4/30/2025
0.14026 %	Barclays Bank PLC	385,007	-1,274,975	3/31/2025
0.13852 %	Ordonez (Kathleen P)	380,216	-22,821	4/10/2025
0.13538 %	National Bank of Canada	371,600	371,600	3/31/2025
0.13392 %	J.P. Morgan Securities LLC	367,591	-2,788	3/31/2025
0.12679 %	Susquehanna International Group, LLP	348,013	-522,622	3/31/2025
0.11591 %	IQ EQ Fund Management (Ireland) Limited	318,170	154,688	3/31/2025
0.11462 %	Jane Street Capital, L.L.C.	314,631	-111,371	3/31/2025
0.10965 %	Mellon Investments Corporation	300,986	-2,915,959	3/31/2025
0.10282 %	Citi Investment Research (US)	282,241	44,550	3/31/2025
0.09966 %	Algert Global LLC	273,557	0	3/31/2025
0.09843 %	Nuveen LLC	270,184	0	3/31/2025
0.09641 %	Managed Account Advisors LLC	264,632	-91,685	3/31/2025
0.09503 %	T. Rowe Price International Ltd	260,841	10,721	3/31/2025
0.09458 %	Farmer (Michele)	259,606	-5,195	5/19/2025
0.08814 %	DWS Investments UK Limited	241,947	-1,608	3/31/2025
0.08548 %	Legal & General Investment Management Ltd.	234,635	0	3/31/2025
0.08463 %	UBS Fund Management (Switzerland) AG	232,309	0	3/31/2025
0.08425 %	California State Teachers Retirement System	231,265	0	3/31/2025
0.08294 %	AllianceBernstein L.P.	227,660	26,180	3/31/2025
0.07898 %	Green Alpha Investments	216,794	114,373	3/31/2025
0.07606 %	GSA Capital Partners LLP	208,776	208,776	3/31/2025
0.07464 %	BlackRock Investment Management (UK) Ltd.	204,869	0	3/31/2025
0.07286 %	Ersel Asset Management SGR S.p.A.	200,000	2	4/30/2025
0.07078 %	Independent Financial Partners	194,280	-7,305	3/31/2025
0.06885 %	UBS Asset Management (Switzerland)	188,995	-55,583	3/31/2025
0.06874 %	UBS Switzerland AG	188,684	90,200	3/31/2025
0.06819 %	INTECH Investment Management LLC	187,186	52,044	3/31/2025
0.06775 %	Emerge Canada Inc	185,954	16,033	9/30/2023
0.06696 %	LPL Financial LLC	183,803	-1,419	3/31/2025
0.06406 %	Franklin Advisers, Inc.	175,839	0	3/31/2025
0.06215 %	Fubon Asset Management Company Ltd.	170,592	-1,228	2/28/2025
0.05981 %	Wells Fargo Bank, N.A.	164,184	3,630	3/31/2025
0.05956 %	Envestnet Asset Management, Inc.	163,482	23,359	3/31/2025
0.05822 %	Benjamin Edwards, Inc	159,802	-5,629	3/31/2025
0.05816 %	State of Wisconsin Investment Board	159,645	-2,685	3/31/2025
0.05448 %	Northern Trust Global Investments Limited	149,553	0	3/31/2025
0.05240 %	HRT Financial LP	143,843	143,843	3/31/2025
0.05225 %	MetLife Investment Management, LLC	143,431	-1,948	3/31/2025
0.05167 %	Benjamin F. Edwards & Company, Inc.	141,830	139,408	6/30/2024
0.04980 %	Susquehanna Fundamental Investments, LLC	136,683	-56,201	3/31/2025
0.04974 %	Eidel (Jeffrey)	136,518	76,268	4/10/2025
0.04918 %	Farallon Capital Management, L.L.C.	135,000	0	3/31/2025
0.04882 %	Corebridge Financial Inc.	134,010	-1,985	3/31/2025
0.04713 %	JPMorgan Private Bank (United States)	129,360	9,073	3/31/2025
0.04685 %	Raymond James & Associates, Inc.	128,609	-8,010	3/31/2025
0.04488 %	Clear Harbor Asset Management, LLC	123,184	9,298	3/31/2025
0.04482 %	Vaughan Nelson Investment Management, L.P.	123,029	0	3/31/2025
0.04372 %	Koa Wealth Management, LLC	120,000	0	3/31/2025
0.04308 %	Kim (Susan G)	118,237	40,676	4/10/2025

What values and corporate philosophy does Pacific Biosciences of California represent?

Pacific Biosciences of California Inc represents a commitment to advancing scientific research and innovation in the field of biological sciences. With a strong focus on genetic sequencing technology, Pacific Biosciences is driven by the mission to enable groundbreaking discoveries and provide valuable insights into the complexity of biological systems. The company's corporate philosophy revolves around delivering high-quality, accurate, and scalable sequencing solutions that empower researchers and drive advancements in areas such as personalized medicine, agriculture, and conservation. Pacific Biosciences of California Inc aligns its values with transparency, collaboration, and a dedication to pushing the boundaries of scientific understanding through state-of-the-art technology and research.

In which countries and regions is Pacific Biosciences of California primarily present?

Pacific Biosciences of California Inc is primarily present in the United States of America.

What significant milestones has the company Pacific Biosciences of California achieved?

Pacific Biosciences of California Inc has achieved several significant milestones. Firstly, the company pioneered and developed Single Molecule, Real-Time (SMRT) DNA sequencing technology, revolutionizing biological research and genomic analysis. Secondly, Pacific Biosciences launched its first commercial instrument, the PacBio RS II System, which enabled long-read sequencing with unmatched accuracy. Furthermore, the company introduced the Sequel System, delivering increased scalability, affordability, and more extensive applications. Pacific Biosciences partnered with various renowned research institutions, industry leaders, and government agencies to advance scientific discovery and genomics research worldwide. These accomplishments have positioned Pacific Biosciences of California Inc as a leading provider of innovative genomic solutions, empowering researchers and scientists in deciphering the complexities of biology.

What is the history and background of the company Pacific Biosciences of California?

Pacific Biosciences of California Inc is a leading biotechnology company headquartered in California. Established in 2004, the company focuses on developing innovative solutions for genetic research and targeted sequencing technologies. Pacific Biosciences of California Inc is known for its state-of-the-art DNA sequencing platforms, enabling an in-depth understanding of complex biological systems. With a strong commitment to advancing scientific knowledge, the company has made significant contributions to various fields, including genomics, personalized medicine, and evolutionary biology. Leveraging cutting-edge technology and a dedicated team of experts, Pacific Biosciences of California Inc continues to drive advancements in genetic research and provide valuable insights into the intricacies of life science.

Who are the main competitors of Pacific Biosciences of California in the market?

The main competitors of Pacific Biosciences of California Inc in the market include Illumina Inc., Thermo Fisher Scientific Inc., and Oxford Nanopore Technologies Ltd.

In which industries is Pacific Biosciences of California primarily active?

Pacific Biosciences of California Inc is primarily active in the biotechnology industry.

What is the business model of Pacific Biosciences of California?

The business model of Pacific Biosciences of California Inc is focused on enabling the use of SMRT Sequencing technology to advance scientific research and genomic understanding. The company develops and sells innovative sequencing systems that provide high-quality genetic data with a wide range of applications in areas such as human genetics, plant and animal sciences, and microbiology. Pacific Biosciences combines its proprietary technology with extensive customer support and collaboration to offer reliable sequencing solutions to academic institutions, government organizations, and pharmaceutical companies worldwide. With a strong emphasis on cutting-edge genomics, Pacific Biosciences aims to drive breakthrough discoveries and contribute to advancements in personalized medicine and agricultural biotechnology.

What is the P/E ratio of Pacific Biosciences of California 2025?

The P/E ratio cannot be calculated for Pacific Biosciences of California at the moment.

What is the P/S ratio of Pacific Biosciences of California 2025?

The P/S cannot be calculated for Pacific Biosciences of California currently.

What is the Quality Investing of Pacific Biosciences of California?

The Quality Investing for Pacific Biosciences of California is 6/10.

What is the revenue of Pacific Biosciences of California 2025?

The expected Pacific Biosciences of California revenue is 159.15 M USD.

How high is the profit of Pacific Biosciences of California 2025?

The expected Pacific Biosciences of California profit is -405.62 M USD.

What is the business model of Pacific Biosciences of California

Pacific Biosciences of California Inc. is a company specializing in the development and marketing of DNA sequencing systems. The company was founded in 2004 and is headquartered in Menlo Park, California. Pacific Biosciences' business model focuses on providing DNA sequencing technologies and services to research institutions, pharmaceutical, and biotech companies. The company offers a portfolio of DNA sequencing systems and services to meet the needs of its customers. The product range primarily includes the SMRT (Single-Molecule, Real-Time) Sequencing System, which can analyze single molecules in real time. The SMRT system enables the detection of DNA methylation patterns, RNA transcript variants, fusion genes, and structural variations that cannot be detected by conventional sequencing methods. In addition, Pacific Biosciences also provides various services to support its customers with DNA sequencing. These include sequencing services, data analysis and reporting, as well as training and technical support. The company also has partnerships with other pharmaceutical and biotech companies to support the development of diagnostics and drugs. However, Pacific Biosciences' business model also faces challenges. The competition in the sequencing industry is strong, with established companies like Illumina and Thermo Fisher already holding a large market share. Additionally, the high costs of the systems and services can deter potential customers. The market for DNA sequencing systems is also closely tied to the research market, which is dependent on household budgets that can fluctuate over time. Nevertheless, Pacific Biosciences has experienced strong growth as more research institutions and pharmaceutical and biotech companies seek more advanced methods of DNA sequencing. In recent years, the company has also formed partnerships with companies like Invitae and Agilent Technologies to expand its presence in the diagnostics industry and provide customers with a more comprehensive solution. In summary, Pacific Biosciences' business model is centered around providing DNA sequencing technologies and services. The company offers a variety of products and services to meet the needs of research institutions and pharmaceutical and biotech companies. Pacific Biosciences' escalation model has firmly established it in the industry, and the company is committed to continuously improving and expanding its offerings to remain at the forefront of DNA sequencing technology.

What is the Pacific Biosciences of California dividend?

Pacific Biosciences of California pays a dividend of 0 USD distributed over payouts per year.

How often does Pacific Biosciences of California pay dividends?

The dividend cannot currently be calculated for Pacific Biosciences of California or the company does not pay out a dividend.

What is the Pacific Biosciences of California ISIN?

The ISIN of Pacific Biosciences of California is US69404D1081.

What is the Pacific Biosciences of California WKN?

The WKN of Pacific Biosciences of California is A1C3EQ.

What is the Pacific Biosciences of California ticker?

The ticker of Pacific Biosciences of California is PACB.

How much dividend does Pacific Biosciences of California pay?

Over the past 12 months, Pacific Biosciences of California paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Pacific Biosciences of California is expected to pay a dividend of 0 USD.

What is the dividend yield of Pacific Biosciences of California?

The current dividend yield of Pacific Biosciences of California is .

When does Pacific Biosciences of California pay dividends?

Pacific Biosciences of California pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Pacific Biosciences of California?

Pacific Biosciences of California paid dividends every year for the past 0 years.

What is the dividend of Pacific Biosciences of California?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Pacific Biosciences of California located?

Pacific Biosciences of California is assigned to the 'Health' sector.

Wann musste ich die Aktien von Pacific Biosciences of California kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Pacific Biosciences of California from 7/5/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 7/5/2025.

When did Pacific Biosciences of California pay the last dividend?

The last dividend was paid out on 7/5/2025.

What was the dividend of Pacific Biosciences of California in the year 2024?

In the year 2024, Pacific Biosciences of California distributed 0 USD as dividends.

In which currency does Pacific Biosciences of California pay out the dividend?

The dividends of Pacific Biosciences of California are distributed in USD.

Scope 1 - Direct Emissions
Scope 2 - Indirect emissions from purchased energy
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Percentage of female employees
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

Stock Exchange	Pacific Biosciences of California Ticker
DÜSSELDORF	P09.DU
FRANKFURT	P09.F
MUNICH	P09.MU
NASDAQ	PACB

Pacific Biosciences of California Ticker	Pacific Biosciences of California FIGI
PACB:US	BBG000QKXH20
PACB:UA	BBG001776S60
PACB:UC	BBG001776S79
PACB:UN	BBG001776S97
PACB:UP	BBG001776SB4
PACB:UB	BBG001776SD2
PACB:UM	BBG001776SG9
PACB:UX	BBG001776SH8
PACB:UD	BBG001776SP9
PACB:UW	BBG001776SS6
PACB:UF	BBG001776ST5
PACB:VY	BBG001776SV2
PACB:VJ	BBG001776SW1
PACB:VK	BBG001776SY9
P09:GR	BBG00188TWG2
P09:GF	BBG00188TWH1
P09:GD	BBG00188TWJ9
P09:GS	BBG00188TWL6
P09:GM	BBG00188TWM5
P09:GB	BBG00188TWN4
P09:TH	BBG00188VY66
P09:QT	BBG008B3NKN8
PACBEUR:EO	BBG008B8PQ89
PACBEUR:XH	BBG008B8PQC4
PACBEUR:XF	BBG008B8PQF1
PACBEUR:XE	BBG008B8PQH9
PACBEUR:XJ	BBG008B8PQJ7
PACBEUR:XL	BBG008B8PQK5
PACBEUR:XG	BBG008B8PQL4
PACBEUR:XO	BBG008B8PQM3
PACBEUR:XS	BBG008B8PQR8
PACBEUR:XA	BBG008B8PQS7
PACBEUR:E1	BBG008B8PQT6
PACBEUR:XT	BBG008B8PQV3
PACBEUR:XW	BBG008B8PQW2
PACBEUR:XU	BBG008B8PQX1
PACBEUR:XV	BBG008B8PQZ9
PACBEUR:EU	BBG008B8PR14
PACB:VF	BBG00DJGJ5Y6
PACBEUR:XX	BBG00JN8BS47
PACBUSD:X2	BBG00JRFF384
PACBUSD:XB	BBG00JRFF393
PACBUSD:XH	BBG00JRFF3C9
PACBUSD:XF	BBG00JRFF3F6
PACBUSD:XE	BBG00JRFF3H4
PACBUSD:XJ	BBG00JRFF3J2
PACBUSD:XL	BBG00JRFF3K0
PACBUSD:XG	BBG00JRFF3L9
PACBUSD:XO	BBG00JRFF3M8
PACBUSD:XS	BBG00JRFF3R3
PACBUSD:XA	BBG00JRFF3S2
PACBUSD:E1	BBG00JRFF3T1
PACBUSD:XT	BBG00JRFF3V8
PACBUSD:XW	BBG00JRFF3W7
PACBUSD:XU	BBG00JRFF3X6
PACBUSD:XV	BBG00JRFF3Y5
PACBUSD:XM	BBG00JRFF3Z4
PACBUSD:XQ	BBG00JRFF419
PACBUSD:XX	BBG00JRFF428
PACBUSD:XZ	BBG00JRFF437
PACBUSD:EU	BBG00JRFF455
PACBGBP:XS	BBG00KWXGM56
PACBGBP:XH	BBG00KWXGM83
PACBGBP:XF	BBG00KWXGMB9
PACBGBP:XE	BBG00KWXGMD7
PACBGBP:XJ	BBG00KWXGMF5
PACBGBP:XL	BBG00KWXGMG4
PACBGBP:XG	BBG00KWXGMH3
PACBGBP:XO	BBG00KWXGMJ1
PACBGBP:XA	BBG00KWXGMN6
PACBGBP:E1	BBG00KWXGMP4
PACBGBP:XT	BBG00KWXGMQ3
PACBGBP:XW	BBG00KWXGMR2
PACBGBP:XU	BBG00KWXGMS1
PACBGBP:XV	BBG00KWXGMT0
PACBGBP:XM	BBG00KWXGMV7
PACBGBP:XQ	BBG00KWXGMX5
PACBGBP:XX	BBG00KWXGMY4
PACBGBP:XZ	BBG00KWXGMZ3
PACBGBP:EU	BBG00KWXGN18
PACBN:PO	BBG00MK1HW98
PACBN:L3	BBG00MK1HZX4
PACBN:B3	BBG00MK1J130
PACB:VG	BBG00X1NT637
PACB:VP	BBG00X1S7Q45
PACBN:L1	BBG00Y92JYP9
P09:GZ	BBG01357XF01
P09:LA	BBG018H947L0
P09:LU	BBG018J2S8G1

2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025e	2026e	2027e	2028e	2029e	2030e
1	2	2	0	0	1	33	26	28	60	92	90	93	78	90	78	130	128	200	154	159	188	232	266	302	470
-	100.00	-	-	-	-	3,200.00	-21.21	7.69	114.29	53.33	-2.17	3.33	-16.13	15.38	-13.33	66.67	-1.54	56.25	-23.00	3.25	18.24	23.40	14.66	13.53	55.63
3,800.00	1,900.00	1,900.00	-	-	100.00	39.39	146.15	21.43	38.33	57.61	48.89	36.56	32.05	37.78	41.03	44.62	40.63	28.00	24.68	23.90	20.21	16.38	14.29	12.58	8.09
0	0	0	0	0	1	13	0	6	23	53	44	34	25	34	32	58	52	56	38	0	0	0	0	0	0
-10	-11	-21	-43	-87	-140	-109	-94	-79	-66	-31	-74	-92	-102	-84	29	-181	-314	-306	-309	-405	-145	-113	-92	-95	-19
-	10.00	90.91	104.76	102.33	60.92	-22.14	-13.76	-15.96	-16.46	-53.03	138.71	24.32	10.87	-17.65	-134.52	-724.14	73.48	-2.55	0.98	31.07	-64.20	-22.07	-18.58	3.26	-80.00
50.1	50.1	50.1	50.1	50.1	52.9	53.9	55.7	62.8	70.5	75.6	89.1	105.7	135.1	152.5	175	204.1	224.6	253.63	274.49	0	0	0	0	0	0
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Unlimited access to the most powerful analytical tools in finance.

Price

Price

TickerPACB

ISINUS69404D1081

WKNA1C3EQ

Pacific Biosciences of California stock price

Price

Overview

Intraday Feature

Total Return and Relative Price Change

Interpretation and Investment

Pacific Biosciences of California Stock Price History

Pacific Biosciences of California Revenue, EBIT, Net Income US69404D1081 · A1C3EQ

Revenue, EBIT and Profit

Understanding Revenue, EBIT, and Income

Yearly Analysis and Comparisons

Utilizing Expectations for Investment

Investment Insights

Pacific Biosciences of California Revenue, EBIT and net profit per share

Pacific Biosciences of California Income Statement, Balance Sheet, Cash Flow Statement

Keystats

Revenue and Growth

Gross Margin

EBIT and EBIT Margin

Income and Growth

Shares Outstanding

Interpreting Year to Year Comparison

Expectations and Predictions

Balance Sheet

Understanding the Balance Sheet

Assets

Liabilities

Equity

Year-to-Year Analysis

Interpreting the Data

Pacific Biosciences of California stock margins US69404D1081 · A1C3EQ

Margin

Understanding Gross Margin

EBIT Margin Analysis

Revenue Margin Insights

Interpreting Expectations

Comparative Analysis

Pacific Biosciences of California Margin History

Pacific Biosciences of California Stock Sales Revenue, EBIT, Earnings per Share US69404D1081 · A1C3EQ

Revenue, EBIT and Earnings per share

Revenue Per Share

EBIT Per Share

Income Per Share

Expected Values

Pacific Biosciences of California Revenue, EBIT and net profit per share

Pacific Biosciences of California business model

Pacific Biosciences of California SWOT Analysis

Strengths

Weaknesses

Opportunities

Threats

Pacific Biosciences of California Revenue by Segment US69404D1081 · A1C3EQ

Revenue by Segment

Overview of Revenue by Segment

Interpretation and Use

Investment Strategy

Pacific Biosciences of California Revenue by Segment

Pacific Biosciences of California Revenue by Region US69404D1081 · A1C3EQ

Revenue by Segment

Overview of Revenue by Region

Interpretation and Usage

Investment Strategy

Pacific Biosciences of California Revenue by Segment

The World’s Best Investors Are On Eulerpool

Pacific Biosciences of California Eulerpool Fair Value

Fair Value

Understanding Fair Value

Income-Based Fair Value

Revenue-Based Fair Value

Dividend-Based Fair Value

Expectations and Forecasts

Comparative Analysis

Pacific Biosciences of California historical P/E ratio, EBIT multiple, and P/S ratio

The World’s Best Investors Are On Eulerpool

Ticker
PACB

ISIN
US69404D1081

WKN
A1C3EQ